경보제약

214390KOSPI

46.0 / 100

Reference Date: 2026-10-23

Financial Score20.5 / 40

News Sentiment12.5 / 25

Momentum6.0 / 20

Disclosure7.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Slightly down 3.9% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Gyeongbo Pharm, established in 1987, is a specialty pharmaceutical company specializing in raw material drugs, selling cardiovascular medications, inhalation anesthetics, and general pharmaceuticals. With raw material pharmaceuticals revenue at 137.3 billion KRW and finished pharmaceuticals at 96.8 billion KRW in 2024, the company is preparing to enter the global ADC CDMO market through self-developed technology. It also expands into medical devices and animal health sectors.

Number of Employees

571people

Average Salary

75.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

653.75Industry Average 15.000.0Point

43.6x industry avg (risky)

PBR

0.86Industry Average 1.205.5Point

Lower than industry avg (good)

ROE

0.13Industry Average 8.001.0Point

Well below industry avg

Debt Ratio

18.22Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲10.5% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲11.1% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 1.8% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (7%, downtrend)

Current 5,230Won52-week high 8,55052-week low 4,945

1-month return2.0Point

1m -3.86% (slight drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

1 totalPositive 0Neutral 0Negative 1

Negative[기재정정]주요사항보고서(영업정지)2026-09-30